Mark Wayne Leuchtenberger
Chairman at NEUROSENSE THERAPEUTICS LTD.
Net worth: 131 040 $ as of 2024-03-30
Profile
Mark Wayne Leuchtenberger was the founder of Mercator Therapeutics, Inc. founded in 2009 where he held the position of Director.
He is also the founder of Albor Biologics, Inc., Alvos Therapeutics, Inc. Mr. Leuchtenberger's current jobs include Chief Executive Officer at Spybiotech Ltd.
since 2022, Chairman at Neurosense Therapeutics Ltd.
since 2021, and Director at Wake Forest University.
His former jobs include Chairman, President & Chief Executive Officer at Acusphere, Inc. from 2013 to 2015, President, Chief Executive Officer & Director at Chiasma, Inc. from 2015 to 2016, President & Chief Executive Officer at Targanta Therapeutics Corp.
from 2006 to 2009, President, Chief Executive Officer & Director at Melinta Subsidiary Corp.
from 2011 to 2013, President & Chief Executive Officer at Therion Biologics Corp.
from 2002 to 2006, President & Chief Executive Officer at Eterna Therapeutics LLC from 2018 to 2019, Chief Executive Officer at Eterna Therapeutics, Inc. from 2017 to 2019, Non-Executive Chairman at Xenetic Biosciences, Inc. from 2014 to 2015, Executive Chairman at Aleta Biotherapeutics, Inc., and Director at EPIX Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc., and Massachusetts Biotechnology Council.
Mr. Leuchtenberger's education includes an undergraduate degree from Wake Forest University and an MBA from Yale School of Management.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-03-14 | 72,000 ( 0.53% ) | 131 040 $ | 2024-03-30 |
Mark Wayne Leuchtenberger active positions
Companies | Position | Start |
---|---|---|
NEUROSENSE THERAPEUTICS LTD. | Chairman | 2021-09-30 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | Director/Board Member | 2013-09-02 |
Wake Forest University | Director/Board Member | - |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | Chief Executive Officer | 2022-07-11 |
Former positions of Mark Wayne Leuchtenberger
Companies | Position | End |
---|---|---|
ETERNA THERAPEUTICS INC. | Chief Executive Officer | 2019-11-30 |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Chief Executive Officer | 2019-11-30 |
CHIASMA, INC. | Chief Executive Officer | 2016-09-30 |
XENETIC BIOSCIENCES, INC. | Chairman | 2015-04-15 |
ACUSPHERE, INC. | Chief Executive Officer | 2014-12-31 |
Training of Mark Wayne Leuchtenberger
Wake Forest University | Undergraduate Degree |
Yale School of Management | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
ACUSPHERE, INC. | Health Technology |
XENETIC BIOSCIENCES, INC. | Health Technology |
NEUROSENSE THERAPEUTICS LTD. | Health Technology |
ETERNA THERAPEUTICS INC. | Health Technology |
Private companies | 15 |
---|---|
EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Chiasma, Inc.
Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | Health Technology |
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Health Technology |
Mercator Therapeutics, Inc.
Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | Health Technology |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Health Services |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | Health Technology |
Albor Biologics, Inc. | |
Alvos Therapeutics, Inc.
Alvos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Arrowhead Pharmaceuticals, Inc., Alvos Therapeutics, Inc. develops novel cancer drugs. The private company is based in Wellesley, MA. The company was founded by Mark Wayne Leuchtenberger. Alvos Therapeutics was acquired by Arrowhead Pharmaceuticals, Inc. on April 11, 2012 for $25.50 million. | Health Technology |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | Health Technology |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Health Technology |
Aleta Biotherapeutics, Inc.
Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Commercial Services |
- Stock Market
- Insiders
- Mark Wayne Leuchtenberger